The brand new tips for using monoclonal antibodies (mAbs) printed in Neurodegenerative Ailments, function exemplary medical suggestions for clinicians and healthcare suppliers, supporting the development of Alzheimer’s illness therapy in Switzerland.
The Swiss Reminiscence Clinics (SMC) community, a gaggle of specialised clinics in Switzerland that diagnose and deal with sufferers with dementia, has launched new nationwide tips on using anti-amyloid mAbs – comparable to Lecanemab and Donanemab – for treating Alzheimer’s illness in Switzerland. Lecanemab is now additionally licensed by the European Fee below strict circumstances.
Printed within the 11 April 2025 subject of Neurodegenerative Ailments, a Karger journal, the paper represents a coordinated effort by the SMC community to make sure protected, efficient, and moral implementation of those rising therapies. Serving as a medical follow information for clinicians and healthcare suppliers, it facilitates the implementation of rising therapy choices within the area of Alzheimer’s illness.
The paper outlines standards for affected person choice, biomarker affirmation, APOE genotyping, ARIA monitoring by way of MRI, and the infrastructure required to assist protected therapy supply. It additionally emphasizes the significance of knowledgeable consent and recommends the creation of a nationwide affected person registry.
The rules stem from interdisciplinary discussions between clinicians within the SMC network–neurologists, geriatricians, old-age psychiatrists, neuropsychologists, neuroradiologists, and affected person organizations, together with representatives of educational and non-academic reminiscence clinics–between August 2023 and December 2024. They supply the primary country-specific framework for integrating mAbs into medical follow.
In a joint assertion, lead authors Dr. med Ansgar Felbecker and Professor Giovanni B. Frisoni, commented: “We constructed an skilled group of specialists to offer suggestions in Switzerland on when to make use of anti-amyloid monoclonal antibodies within the care of Alzheimer’s illness sufferers. Our hope is that this steering will assist with the approval of those new medication in different international locations for sufferers who qualify for this care.”
Whereas the paper supplies a country-specific framework for using mAbs in medical routine, the authors hope that as Alzheimer’s illness care enters a brand new therapeutic period, these tips can steadiness innovation with medical duty—providing a mannequin for different nations navigating related questions.
It’s nice that the journal Neurodegenerative Ailments serves as a house for such necessary steering that has the potential to impression hundreds of sufferers,”
Professor Gilles Allali, Editor in Chief of Neurodegenerative Ailments, Karger Publishers
“The most recent tips put ahead by Swiss specialists really have the potential to rework Alzheimer’s illness care throughout the globe.”
